As the preclinical drug testing in organoids helps accurately predict the clinical treatment outcome (29,52,53,54), the observed efficacy of the multiple low-dose treatment with WEE1 and PKMYT inhibitors suggests that the respective tumours may have responded to the therapeutic combination. This evidence concerns the gene WEE1 and neoplasm.